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Fluselenamyl: A Novel
Benzoselenazole Derivative for
PET Detection of Amyloid Plaques
(Aβ) in Alzheimer’s Disease
G. S. M. Sundaram1,2, Dhruva D. Dhavale3,4, Julie L. Prior1,2, Ping Yan3,4, John Cirrito3,4,5,
Nigam P. Rath6, Richard Laforest2, Nigel J. Cairns5,7, Jin-Moo Lee2,3,4,8, Paul T. Kotzbauer3,4 &
Vijay Sharma1,2,3,8
Fluselenamyl (5), a novel planar benzoselenazole shows traits desirable of enabling noninvasive
imaging of Aβ pathophysiology in vivo; labeling of both diffuse (an earlier manifestation of neuritic
plaques) and fibrillar plaques in Alzheimer’s disease (AD) brain sections, and remarkable specificity
for mapping Aβ compared with biomarker proteins of other neurodegenerative diseases. Employing
AD homogenates, [18F]-9, a PET tracer demonstrates superior (2–10 fold higher) binding affinity than
approved FDA tracers, while also indicating binding to high affinity site on Aβ plaques. Pharmacokinetic
studies indicate high initial influx of [18F]-9 in normal mice brains accompanied by rapid clearance in
the absence of targeted plaques. Following incubation in human serum, [18F]-9 indicates presence of
parental compound up to 3h thus indicating its stability. Furthermore, in vitro autoradiography studies
of [18F]-9 with AD brain tissue sections and ex vivo autoradiography studies in transgenic mouse brain
sections show cortical Aβ binding, and a fair correlation with Aβ immunostaining. Finally, multiphotonand microPET/CT imaging indicate its ability to penetrate brain and label parenchymal plaques in
transgenic mice. Following further validation of its performance in other AD rodent models and
nonhuman primates, Fluselenamyl could offer a platform technology for monitoring earliest stages of
Aβ pathophysiology in vivo.
Alzheimer’s disease (AD) is the most frequent form of dementia which affects 24 million people worldwide, and
also lacks effective therapeutic interventions1. Without successful treatment or prevention, the number of affected
individuals can be expected to grow exponentially to 13–16 million in the United States and to >100 million
globally by 2050. The failure of clinical drug trials to reverse clinical symptoms indicates that for a given treatment
to be effective, it most likely needs to be prescribed at a preclinical stage before the symptomatic expression of the
disease. Therefore, there is an urgent need to identify and validate biomarkers that are present at preclinical stages.
Importantly, several biomarkers identified for diagnosis, staging, and assessment of therapeutic effects are (but
not limited to): amyloid deposition, changes in CSF levels of tau, hyperphosphorylated tau (p-tau), or Aβ1–42, and
reduced metabolism monitored via fluorodeoxyglucose (FDG) PET imaging2–5. While amyloid deposition and
variations in CSF levels of tau and Aβrepresent pathophysiological markers thus relevant for disease diagnosis,
the reduced metabolism (FDGPET) or atrophy (MRI) demonstrate topographic markers indicating a progression of the disease. Furthermore, literature precedents of last decade indicate that AD pathological changes (Aβ
deposition and NFT formation) occur years prior to onset of symptoms6. For diagnosis of AD, several PET radiopharmaceuticals targeting Aβdeposition, such as, [11C]-PiB7, [18F]-FDDNP8, [11C]-SB-139, and [18F]-AV-4510,
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Figure 1. Chemical synthesis of Fluselenamyl 5 and [18F]-9 (PET tracer).

[18F]-AZD469411,12 have been investigated in humans. In addition, [125I/131I]-TZDM, [125I]-IMPY, [123I]-DRM106
and [123I]-ABC577, have also been investigated for SPECT applications13–15. While [11C]-PiB has been most
intensely studied, [18F]-AV-4516, [18F]-Flutemetamol (Vizamyl)17,18 and [18F]-Florbetaben (Neuraceq )19–21 have
been recently approved by FDA for Aβimaging. Importantly, both [18F]-AV-4522 and [11C]-PiB show promising
results in humans and excellent correlation with FDG7. Recent investigations examining [3H]-PiB and [18F]-AV4523 binding to AD homogenates also indicate multiple binding sites on Aβ24 thus mandating development of new
tracers to study Aβpathophysiology. To further supplement the existing armamentarium of FDA approved Aβ
imaging agents, earlier we have shown that a heterocyclic fluorescent molecule is capable of traversing the BBB
to label Aβplaques in brains of APP+/−/PS1+/− mice and also indicates sensitivity for detecting diffuse plaques in
autopsy confirmed AD human tissues25,26. Although the PET counterpart showed high first pass extraction into
the brains of normal mice and Aβlabeling in brain frontal cortex of APP+/−/PS1+/− mice, its binding affinity to
AD homogenates was 5–10 fold inferior compared with two FDA approved agents27. Importantly, this template
scaffold of our first generation agent comprised a benzothiazole moiety, a pharmacologically active constituent
with widespread medicinal chemistry applications. Compared with benzothiazole derivatives, investigations on
biological activity of benzoselenazoles have not gained much attention primarily due to a lack of convenient and
cost-efficient chemical methodologies28. To our knowledge, benzoselenazoles derivatives represent an entirely
novel class of Aβdiagnostic agents. Herein, we report synthesis, characterization and crystal structure of (Z)-5(2-(5-(2-fluoroethoxy)benzo[d][1,3]selenazol-2-yl)vinyl)-N,N-dimethylpyrimidin-2-amine (Fluselenamyl: 5),
F-18 labeled radiotracer ([18F]-9), and perform its preclinical validation to evaluate its potential to serve as an
Aβ-targeted PET radiopharmaceutical for monitoring plaque burden in AD. Fluselenamyl demonstrates potent
binding to Aβfibrils, autopsy confirmed AD homogenates, traverses the blood brain barrier (BBB) to detect Aβ
plaques in a transgenic mice model, and is highly specific for probing Aβplaques in AD.

™

Materials and Methods

Material details, organic synthesis procedures, analytical characterization of all intermediates including the final
Fluselenamyl (1, 2, 3, 4, 5, 6, 7, and 8) and radiochemistry for synthesis of the PET tracer [18F]-9 are described
in supporting information. Additionally, X-ray crystallographic details for 5; Aβbinding assays (Fibrils and AD
homogenates) using 5 and [18F]-9; histochemical staining of 5 with transgenic mice brain cross sections, and
AD brain sections; human serum stability of [18F]-9; autoradiography of [18F]-9 with AD human brain sections
and ex vivo brain sections of APP/PS1 and WT mice biodistribution studies of [18F]-9 in FVB mice; multiphoton imaging using 5 in transgenic mice, and finally microPET/CT imaging details of [18F]-9 in age-matched
transgenic mice and their WT counterparts are also included in the supporting information. While postmortem
brain tissues from autopsy-confirmed AD patients and their approximate age-matched healthy controls were
obtained through the Knight Alzheimer’s Disease Research Center (ADRC) Washington University School of
Medicine, and processed according to a protocol approved by institutional ADRC executive committees, the animal procedures were approved by the Washington University Animal Studies Committee (Protocols #20150147,
PI: Sharma; protocol #20140182, PI: Jin-Moo Lee). All methods were carried out on animals and human tissues
in “accordance” with the approved guidelines.

Scientific Reports | 6:35636 | DOI: 10.1038/srep35636

2

www.nature.com/scientificreports/

Figure 2. The projection view of 5 showing crystallographic numbering scheme. Atoms are represented by
thermal ellipsoids corresponding to 30% probability.

Results and Discussion

Our strategic design for obtaining a second generation Aβ-targeted agent involved five functional components
described earlier25. Incorporating those characteristic features into a template scaffold, the Aβtargeted probe
5 was synthesized as shown (Fig. 1; synthetic chemistry details are in supporting information). For synthesis, 5-methoxy-2-methylbenzo[d][1,3]selenazole 2 was obtained using literature procedures from N-(acetyl)
benzoyl-2-iodoaniline 1, using Woolins reagent under microwave conditions29 and condensed with 2-(dimethylamino)pyrimidine-5-carbaldehyde in an aqueous potassium hydroxide (50%) solution dissolved in DMSO to
obtain 3. Following purification, 3 was demethylated in the presence of BBr3 to yield the phenolic derivative 4.
Finally, 4 was alkylated with 2-fluoroethyl-4-methylbenzene sulfonate (prepared using literature procedure30)
in the presence of cesium carbonate to obtain 5. Alternatively, 4 was treated with (2-bromoethoxy)(tert-butyl)
dimethylsilane in the presence of cesium carbonate to obtain (Z)-5-(2-(5-(2-((tert-butyldimethylsilyl)oxy)ethoxy)benzo[d][1,3]selenazol-2-yl)vinyl)-N,N-dimethylpyrimidin-2-amine (6). Upon treatment with TBAF, its
corresponding deprotected alcohol 7 was obtained. Following treatment of 7 with tosyl-chloride, 8 the precursor
ligand for synthesis of the PET tracer was obtained. Finally, 8 was also treated with TBAF to obtain 5 via nucleophilic displacement. All intermediates 1, 2, 3, 4, 6, 7, 8 and the final compound 5 were characterized via standard
analytical methods. Additionally, 5 was also analyzed for uniformity and purity, on a semi-preparative C-18
column (Phenomenex), using an HPLC system. Compound 5 eluted as a single chemical entity, with a retention
time of 10.5 minutes thus indicating purity of the molecule. For determination of the solid-state structure, crystals suitable for X-ray analysis were obtained via a vapor diffusion method, involving slow diffusion of methanol
into a DCM solution containing 1% ACN of 5. The benzoselenazole derivative 5 crystallized in a monoclinic
space group P 21/n. The ORTEP drawing showing the crystallographic numbering scheme for 5 is illustrated
in Fig. 2. The crystal structure of 5 shows a planar molecule with the F atom displaced from the mean plane by
1.005 Å (mean plane deviation for the molecule except F = 0.048 Å). The heterocyclic molecule 5 indicates presence of both inter and intra-molecular hydrogen bonding (SI, Fig. 1). Noticeably, H13 forms intra-molecular
H bond to N1 at 2.22 Å thus comprising a bond angle of C13-H13-N1 = 147°. Additionally, two intermolecular hydrogen bonds involve the N atoms N2 from the ring and the solvent N, N1s [C3-H3….N2 (1.5-x, y-0.5,
z-0.5) = 2.61 Å and the bond angle around H3 =  164.5°; C15-H15a…N1s (1+x, y, z) = 2.68 Å and the angle
around H15a = 170.5°]. While search of the Cambridge Crystallographic database does not show organic scaffolds sharing a similar arrangement of atoms around Se in the molecule, the closest chemical structure for comparative analysis remains the first generation Aβtargeted molecule reported earlier25. Importantly, the chemical
structures of 5 and its first generation benzothiazole derivative counterpart (C18H18FN3OS) are identical except
that Se is swapped with S (while the six membered aromatic ring of 5 possesses 2Ns, the aromatic ring of the benzothiazole derivative contains only one N atom). Therefore, Se-C interatomic distances (1.868(7) and 1.917(7) Å)
in 5 are larger compared to the S-C distance (1.728(2) and 1.762(2) Å) in earlier reported benzothiazole derivative
thus consistent with a larger size of the selenium atom. Furthermore, the bond angle around the Se atom of 5 is
also significantly narrower than that of benzothiazole derivative (84.6° vs 89.1°). Overall, comparative analysis
indicate both 5 and its first generation counterpart25 share planar geometry with the F atoms displaying out of
plane deviation. Finally, NMR spectral data of 5 was also consistent with the crystal structure thus indicating
the presence of identical structures both in solid and solution state (JH-H = 7.4 Hz; alkene protons indicating the
presence of Z isomer) and the results are in accord with the first generation Aβ agent25.
For assessing the ability of 5 to bind Aβplaques; preliminary binding assays with preformed Aβ1–42 fibrils were
performed in PBS. Following excitation at 392 nm, fluorescence spectrum of 5 recorded in PBS containing 1%
ethanol showed a broad emission peak at 450–540 nm with Emax at 490 nm. Upon incubation with preformed Aβ
(1–42) aggregates, the peak (490 nm) showed remarkable enhancement in fluorescence indicating binding to Aβ
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Figure 3. Staining of brain hippocampus tissue sections from APP+/−/PS1+/− 10 months old mice using 5
(100 nM) or immunostained with mouse monoclonal antibody (mHJ3.4) conjugated to Alexa 568 (positive
control). Arrows indicate labeling of Aβplaques (arrows, extracellular Aβ; arrow head, Cerebral Amyloid
Angiopathy (CAA). The slides were analyzed Nikon Eclipse E800 epifluorescence microscope. Magnification:
10X; Top Inset; 20X.

Figure 4. Binding of anti-Aβantibody (10D5, Eli Lilly, (A)), 5 (B), and thioflavin S (C) to Aβplaques in AD
brain near/adjacent tissue sections. Amyloid in postmortem frontal lobe of a 90-year-old male. Magnification:
200X. (A): diffuse Aβplaques and an arteriole with Aβdeposits (cerebral amyloid angiopathy); 10D5
immunohistochemistry. (B): section stained with 5 containing the same arteriole as in (A). There are numerous
diffuse Aβplaques (arrows) and compact plaques (arrow head) and the vessel is also stained. (C): Thioflavin S
reveals amyloid in blood vessels and compact plaques (arrow head). The same blood vessel (asterisk) is labeled
in (A–C). Similar results were obtained with more than three independent experiments.

aggregates, similar to enhancement in fluorescence of thioflavin T in PBS (a positive control; data not shown).
Additionally, it is also noteworthy that no fluorescence was observed using Aβaggregates alone in PBS following
excitation at 392 nm (a negative control). Preliminary binding assays of 5 with preformed Aβ1–42 aggregates (using
a single site binding model) indicated saturable binding with a Kd =  1.58 ± 0.05 nM (SI, Fig. 2).
Aβimaging ligands and disease-modifying therapeutics have been investigated using APP+/−/PS1+/− transgenic mice models31,32. Further, we assessed the ability of 5 to stain ex vivo brain sections (50 μm) of age-matched
APP+/−/PS1+/− mice and their WT (BL/6) counterparts, using established procedures33. As a positive control,
anti-Aβmonoclonal antibody (mHJ3.4 conjugated to Alexa Fluor 568) was used34. Brain sections of 10 month
old APP+/−/PS1+/− mice, using mHJ3.4-AF568 conjugate showed distinct staining of Aβ(Fig. 3) compared with
none in WT counterparts (SI, Fig. 3). Similarly, 5 (100 nM) demonstrated abundant staining of Aβplaques in the
hippocampus brain sections in APP+/−/PS1+/− mice. By comparison, 5 indicated no staining in 10 months old
WT mice (SI, Fig. 3) thus indicating its target specificity. While nearly 1:1 correlation was apparent for Aβ extracellular plaques (Fig. 3; right panel; arrows), 5 also demonstrated substantially higher sensitivity for labeling CAA
compared with anti Aβantibody thus consistent with slight variations in staining patterns observed between a
small organic molecule and a large antibody25.
To further assess ability of the 5 to label Aβplaques in human brain, staining experiments were also performed
with postmortem tissues from clinically-characterized AD patients35,36 As a positive control, a highly specific
anti-Aβantibody (10D5, Eli Lilly, Indianapolis, IN) was used to ascertain the presence of Aβplaques (Fig. 4A),
using well-established procedures for assessment of Aβplaques in postmortem brain37. Importantly, 5 (2 μM)
demonstrated strikingly distinct labeling of Aβplaques in the tissue sections of frontal lobe of a 90-year-old
male with AD (Fig. 4B) and absence of Aβplaques in normal controls (SI, Fig. 4A,D), therefore indicating target
specificity. Noticeably, 5 also indicated proficient and distinct labeling of plaque and leptomeningeal vessels (cerebral amyloid angiopathy; CAA) (Fig. 4B). These data are consistent with other unlabeled counterparts of FDA
approved PET agents38. Furthermore, thioflavin S, an amyloid staining dye showed staining of amyloid in the
blood vessel (CAA) and indicated only weak staining of diffuse plaques (Fig. 4C). Importantly, 5 demonstrated
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Figure 5. Binding of [18F]-9 with AD homogenates (A,C) and Aβ1-42 fibrils (B,D). Aβ1-42 fibrils and AD
homogenates were incubated with increasing concentrations of [18F]-9. Representative plots of specific
binding versus [18F]-9 concentration are shown for AD homogenates in (A) and Aβfibrils in (B). Data points
represent mean +/−standard deviations (n = 3). The data was analyzed by curve fitting to a one-site binding
model using a nonlinear regression. Scatchard plots of binding are shown for AD homogenates (C) and Aβ1-42
fibrils (D) and are consistent with one-site binding model. Similar results were obtained in two independent
experiments. Fluorescence binding assays of 5 with Aβ1-42 fibrils also indicated a saturable specific binding with
a Kd =  1.58 ± 0.05 nM (SI, Fig. 2).

labeling of numerous diffuse Aβplaques (Fig. 4B) and specificity for Aβplaques in AD compared with biomarkers of other neurodegenerative diseases (SI, Fig. 4A,B). This high specificity of 5 for Aβcould be attributed to
presence of a benzoselenazole ring within Fluselenamyl. Overall, the ability and sensitivity of 5 to detect diffuse plaques and specificity for AD could represent an important advancement to enable PET imaging of mildly
demented individuals, prior to onset of symptoms6.
For performing additional bioassays and correlating Aβbinding data of 5 obtained via fluorescence assay, the
PET counterpart [18F]-9 was synthesized via standard nucleophilic substitution, employing 2,2,2-kryptofix/18F
and tosylate analog 8. Following reaction and Sep-Pak treatment to separate free fluoride, the crude mixture was
purified on a C-18 column, using a radio-HPLC system, with an overall radio-chemical yield of 35% (radiochemical purity >99%; specific activity (1700–2000 Ci/mmol). Furthermore, [18F]-9 was also characterized by spiking
with an analytically characterized sample of an unlabeled counterpart 5 (SI Fig. 5), prior to injection on the
radio-HPLC. The fraction eluting at Rt = 10.5 min was collected, concentrated, and resuspended in PBS/ethanol
(95/5) for all radiotracer bioassays.
For assessing the ability of [18F]-9 to bind Aβplaques; binding assays with either AD homogenates or preformed Aβ1–42 aggregates were performed in 30 mM Tris, pH 7.4 buffer supplemented with 0.1% BSA 39.
Nonspecific binding was determined in the presence of 5 (1 μM) as a competitor. Overall, the binding assay
of [18F]-9 with AD homogenates and Aβ1–42 fibrils (Fig. 5A–D), indicates a saturable specific binding with
Kd = 1.7 nM (Bmax = 546 pmol/g wet wt.) and 1.6 nM (Bmax = 1.3 pmol/nmol), respectively (Fig. 5A,B). Scatchard
plots of the binding data indicate that [18F]-9 binds to a single high affinity site on AD homogenates and Aβ1–42
fibrils (Fig. 5C,D). Importantly, the binding affinity of [18F]-9 with autopsy confirmed AD homogenates is significantly superior to that of other FDA approved Aβ-targeted probes ([18F]-Florbetaben, 16 nM40; [18F]-AV-45,
3.7 nM41; [18F]-Flutemetamol, 6.7 nM)42. Previously, the incorporation of pyrimidine ring into benzothiazole has
been shown to decrease binding affinity of the molecule to Aβ fibrils43. However, the design of Fluselenamyl
includes an incorporation of pyrimidine ring into benzoselenazole, wherein the atomic radius of selenium
(115 pm) is much larger than that of sulfur atom (100 pm) present within benzothiazole43, resulting in longer
bond lengths involving selenium with neighboring atoms of the 5-membered ring (as evident from crystal structure data of 5), and the presence of an additional double bond between two ring systems (benzoselenazole and
pyrimidine ring) thus generating a relatively better flow of electrons consistent with planarity of the molecule
Scientific Reports | 6:35636 | DOI: 10.1038/srep35636
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Figure 6. Autoradiography images of [18F]-9 binding in an AD frontal cortex section following incubation
with either [18F]-9 (2 nM) alone (A) or in the presence of 5 (1 μM, C). Fluorescent immunostaining of sections
(A) and (C) with an anti-Aβantibody conjugate is shown in (B) and (D), respectively. The autoradiography
images demonstrate laminar distribution of [18F]-9 binding in cortex, which correlates with the distribution of
Aβplaques detected by fluorescent immunostaining, and binding of [18F]-9 is inhibited by excess cold ligand
5 (1 μM, C).

and observed strong fluorescence enhancement of 5 upon binding to Aβcompared with analogues of PiB42.
Additionally, the incorporation of dimethylamino group into the pyridine ring has been shown to promote selectivity for Aβ44. Therefore, the higher binding affinity of 5 to Aβplaques could be attributed to these combined
variations in the scaffold.
Literature precedents indicate the presence of at least three different binding sites, characterized as BS1, BS2
and BS3 on the Aβ fibrils in vitro24 and extracts from AD homogenates23. A recent binding study using homogenates from AD confirmed human tissues and their control counterparts also indicates the presence of multiple
binding site models for the amyloid tracers23, wherein [18F]-AV-45 and [11C]-PiB have been shown to bind to
two different binding sites, a high-affinity site (visualized by PET) and a low affinity site. Additionally, while
BF-227 shows binding to BS3, the FDDNP has been postulated to bind only to BS223. Overall, these investigations
indicate that different PET tracers may be beneficial to better understand Aβ pathophysiology in vivo. To assess
the binding site targeted by [18F]-9 on AD homogenates, binding assays were also performed in the presence
of unlabeled analytically characterized samples of PiB, IMPY, and Chrysamine G. While no displacement was
observed with Chrysamine G, significant displacement of [18F]-9 specific binding was observed in the presence of
unlabeled PiB and IMPY, suggesting that radiotracer [18F]-9 binds to the same high affinity site on AD homogenates. This is further supported by the observation that the Ki values obtained from analysis of the competition
assays (Ki = 4.9 nM for PiB, Ki = 6.3 nM for IMPY) are also consistent with previously reported Kd values obtained
in assays measuring direct binding of these tracers to AD homogenates. Further, to evaluate ability of [18F]-9 for
labeling Aβin autopsy confirmed human brain sections, autoradiography and immunohistochemical correlations
were also performed. Following incubation of AD frontal cortex sections (12 μm) with [18F]-9 (2 nM) for 60 min,
the agent showed labeling of cortical Aβplaques and the binding was inhibited upon incubation in the presence
of 5 (1 μM) (Fig. 6A,C). These data indicate sensitivity and specificity of the [18F]-9. Additionally, immunohistochemical staining of these sections using anti- Aβ-antibody indicated the presence of Aβplaques in the cortex of
these sections (Fig. 6B,D) thus demonstrating excellent correlation of immunohistochemical staining data with
that of autoradiography data.
For biomedical imaging applications, the signal is a net function of target/background ratio. In PET imaging, this signal results from detection of γ-photons arising from annihilation events of positrons and imaging
resolution is also dependent upon energy associated with a given radionuclide. Resultant radioactive metabolites could also contribute to nonspecific binding or compete with the parental tracer for binding to the target. Therefore, it is also important to investigate metabolic stability of the radiotracer to explicitly confirm
Scientific Reports | 6:35636 | DOI: 10.1038/srep35636
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Importantly, both [11C]-PiB and [18F]-AV-45 have demonstrated low biological half-lives in serum; while metabolites of [11C]-PiB have been shown to be polar and thus postulated to not penetrate the brain45, two metabolites
of [18F]-AV-45 (desmethylated, 4.5% ID/g; acetylated analogue, 3.3% ID/g at 2 min in normal mice)10 have been
shown to permeate the brain and thus could potentially contribute nonspecific interaction and complicate image
analysis. To perform preliminary evaluation of biological half-life, [18F]-9 was also incubated at 37 °C in human
serum as a function of time, and aliquots were analyzed on radio-HPLC. The presence of a single radio-peak
indicated presence of parental tracer up to 3 h (SI Fig. 6).
To further assess whether or not PET counterpart [18F]-9 administered at tracer concentrations relevant for
nuclear imaging demonstrates optimal kinetics (signal/noise ratios) to enable brain imaging in vivo, quantitative
biodistribution studies in normal mice were performed. Uptake in brain and other critical organs was analyzed
in terms of percent injected dose per gram of the tissue (%ID/g) SI Table 1. For in vivo imaging of Aβ plaques,
the basic pharmacokinetic model in normal brains involves a high initial penetration of the agent, accompanied
by facile clearance due to lack of a binding target. Preliminary biodistribution studies (SI, Table 1) with HPLC
purified [18F]-9 in normal mice show transient brain uptake values of 8.86 ± 0.32% ID/g and 1.66 ± 0.01% ID/g, at
2 min and 120 min post tail-vein injection, respectively, thus providing a 2 min/120 min clearance a ratio of 5.33.
For comparison, brain uptake ratios of [18F]-AV-45 (2 min/2 h) and [18F]-Florbetaben (2 min/4 h) in normal mice
are 4.07 (%ID/g (brain): 2 min: 7.33 ± 1.54; 2 h: 1.80 ± 0.07; 7.33/1.80; 4.07)10 and 5.0 (%ID/g (brain): 2 min: 4.77;
4 h: 0.95; 4.77/0.95; 5.02)46, respectively. Therefore, the brain uptake clearance ratio of [18F]-9 (2 min/120 min)
is 1.3-fold superior to [18F]-AV-45 and is comparable to that of [18F]-Florbetaben in healthy mice. For an agent
to be able to serve as an Aβ-imaging agent, literature precedents indicate that brain uptake ratio (%ID/g; the
earliest time–point; 2–5 min to that of the latest time point; typically for carbon-11; 30–60 min; and F-18, 2 h) of
3.5 or above could be considered as a benchmark for ability of a given agent to cross the blood-brain barrier38.
Additionally, the brain uptake of a given imaging agent is also a net function of several components, such as cerebral regional blood flow, BBB permeability, plasma radiotracer concentration, and free fractions of the radiotracer
in plasma and in the brain. Furthermore, the lipophilicity of a given compound also reflects a critical physicochemical trait for neuroimaging radiotracers due to its direct relationship to membrane permeability, solubility in
water, and entropic contribution to binding. Literature precedents indicate that lipophilic drugs readily cross the
BBB, although other chemical characteristics, including the number of hydrogen bonds, molecular weight, polar
surface area and molecular size are also known to be critical traits for passive transport. Lipophilicity measured
via (log POCT), the octanol/water partition coefficient for non-ionized molecules serves as a good indicator of a
molecule to permeate brain and molecules possessing log P values of 0.9 and 3.0 have been shown to cross the
BBB47. Conversely, radiotracers that are too lipophilic can also bind plasma proteins, undergo fast metabolism,
while also contributing to high nonspecific binding, such as white matter. [18F]-9 demonstrates a log P value
of 1.28 which is similar to that of [11C]-PiB (1.3) but considerably lower than that of [18F]-AV-45 (2.4), and
[18F]-Florbetaben (3.22). While the clearance ratio of 5.33 (%ID/g; 2 min/120 min; SI Table 1) provides evidence
for the ability of [18F]-9 to traverse the BBB in vivo, the log P value of 1.28 could also lead to a low nonspecific
interaction with white matter. Additionally, the agent [18F]-9 excreted from other critical organs over 2 h (SI,
Table 1); a critical factor likely to result in favorable dosimetry; although slight defluorination as a function of
time is also evident from bone accumulation; yet consistent with pharmacokinetic profiles of other FDA approved
agents10,17,18. For assessing directly the ability of radiotracer to traverse the BBB, [18F]-9 (170 μCi) was injected
into a 24 months old APP/PS1 transgenic mouse and its age-matched WT counterpart, and 30 min post tail-vein
injection, the brains were removed, frozen, and sectioned for autoradiography (Fig. 7A–E). Autoradiograms of
the brain sections showed labeling of plaques in cortical regions, in addition to probable off-target binding in
white matter (Fig. 7A). The labeling of plaques was confirmed by staining with anti-Aβmonoclonal antibody
(mHJ3.4 conjugated to Alexa Fluor 568, Fig. 7B) and data show fair correlation with a caveat of some off-target
binding attributed to differences between targeting profiles of a small organic molecule versus the large highly
specific monoclonal antibody (Fig. 7A,B). For ROI analysis of the PET signal in brain section autoradiograms of
transgenic mouse (Fig. 7A) and its WT counterpart (Fig. 7D), we used measured count densities in cortex and
amygdala target regions and compared them with that of hypothalamus as reference region with a low plaque
density as determined by Aβimmunostaining (Fig. 7B). The target/reference ratio (mean ± SD) in the transgenic
mouse was 1.88 ± 0.22 compared to 0.96 ± 0.12 in the WT control mouse (Fig. 7E). Since brain stem was also
devoid of plaques, we also analyzed the above target regions using brain stem as a reference region, and observed
target/reference value in the transgenic to be 0.89 ± 0.1 compared to 0.45 ± 0.07 in the WT mouse.
For assessing viability of molecules as imaging probes in vivo48, various imaging modalities, such as nuclear
imaging (PET/SPECT), optical imaging, and MRI have been used to investigate simultaneously distribution
kinetics and target-receptor specificity. While the resolution of PET and MRI allow in vivo imaging at relatively
moderate resolution, the multiphoton microscopy enables evaluation of kinetics at a sub-micrometer resolution49.
Therefore, this technique enables characterization of probes in small animal models at a significantly high spatial
and temporal resolution49. The generation of various transgenic (tg) animals overexpressing mutant human APP
and/or PS1 and PS2, tg APP mice expressing ApoE isoforms including those for Tau offer attractive models for
unravelling biochemical pathways prevalent in pathophysiology of AD50–54. Of note, compared to single transgenic animal models (APP or PS1), co-expression of PS1 with APP exhibits robust deposition of Aβ months
earlier than APP tg mice alone. Literature precedents indicate Aβdeposition by 2 months of age, with gradual
quantitative increase at six months55. Therefore APP/PS1 mice offers interesting models for evaluation of therapeutics and validation of imaging probes in vivo25. For assessing the ability of 5 to penetrate the BBB, label Aβ
parenchymal plaques, and simultaneously interrogate the pharmacokinetic profiles from nearby brain regions,
direct real-time imaging was performed in transgenic APP+/−/PS1+/− mice. Prior to imaging, dextran-Texas
Red conjugate (33 mg/kg; dissolved in PBS to mark the blood vessels) and 5 (2 mg/kg; dissolved in 20% DMSO
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Figure 7. Ex vivo autoradiography images of 24-mo APP/PS1 Tg and WT control mouse after injection
with [18F]-9. (A) Coronal autoradiography image obtained at 30 min post-injection of [18F]-9 in the 24 months
APP/PS1 Tg mouse. (B) Immunofluorescence staining of the same section with monoclonal anti-Aβ antibody
to assess plaque density. (C,D) Count intensities were determined in three target ROIs (red boxes) for APP/
PS1 Tg (C) and WT control (D), based on high Aβplaque density in the immunostained APP/PS1 Tg section.
Solid red boxes represent the locations of target ROIs in cortex, while dashed red boxes represent the locations
of target ROIs in amygdala. Count intensities were also measured in a reference ROI (hypothalamus) with low
plaque density, represented by green boxes. (E) Levels of tracer activity were analyzed by comparing the target/
reference count intensity ratios for APP/PS1 Tg and WT control mice (mean +  SD, n =  3).
in propylene glycol56) were intravenously administered to anesthetized APP+/−/PS1+/− mice (with cranial windows; supporting information). Following injection, 3D volumes were acquired (by collecting a stack of x-y
sections from surface of the thinned skull to 100 μm deep into the cortex). Compared with barely detectable
auto-fluorescence levels prior to imaging transgenic APP+/−/PS1+/− mice (Fig. 8, first panel), bright fluorescence
appeared almost instantaneously following administration of 5. Fluorescence first appeared in large and small
blood vessels within the brain. Within minutes (10 min), the brain parenchyma was uniformly bright in fluorescence, and Aβdeposits were labeled. While the complete labeling of CAA occurred instantaneously following
injection, the labeling of parenchymal plaques peaked at approximately 10 min. Overall, these data demonstrate
in real time that 5 permeates the brain rapidly, and visualizes parenchymal Aβplaques (Fig. 8).
To directly access the potential of [18F]-9 to bind Aβ plaques in vivo, we performed microPET/CT imaging in
age-matched APP+/−/PS1+/− mice (n = 3) compared their WT counterparts, 5 min-2 h post tail-vein injection.
For any given agent to serve as an Aβ-targeted agent, a pharmacokinetic model would involve an initial high and
equal influx of the tracer into the brains of transgenic and WT mice, followed by clearance of the radiotracer from
brains of WT mice thus demonstrating differential retention in regions of brains, as the agent binds to Aβ plaques
in transgenic mice. Indeed, the [18F]-9 demonstrates a 1.2-folds (p < 0.05) higher retention in transgenic mice
brains consistent with its binding to Aβplaques, while exhibiting clearance of the unbound tracer from brains
of WT counterparts (Fig. 9). Time activity curves (TAC) also indicated higher retention of activity within transgenic mice brains compared with their WT counterparts (Fig. 10). Additionally, ROI (cortical regions) were also
analyzed using linearized method with a reference region (cerebellum) via Reference Logan plot (RefLogan), and
distribution volume ratios (DVR) were obtained. The analysis indicated a statistically significant DVR value of
1.18 for transgenic mice brain compared with that of 1.03 for WT brains. These smaller differences in DVR values
of targeted regions in transgenic mice compared with that of WT counterparts could also be attributed to a lack
of true negative reference region in aged PS1/APP mice57. Similar to [11C]-PiB58,59 and [18F]-Florbetaben60, [18F]-9
shows also considerable retention in extracerebral regions, such as nasal and eye cavities, consistent with presence
of plaques in these rodent models. While literature precedents indicate that [11C]-PiB61 and [18F]-Flutemetamol62
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Figure 8. Real time multiphoton imaging of 5 in brains of APP +/−/PS1+/− transgenic mice: Following
demarcation of blood vessels with dextran-Texas Red, 5 (2 mg/kg) was intravenously injected. A z-stack image
series was acquired using an LSM 510META NLO microscope (Carl-Zeiss Inc). While arrowhead indicates
vascular Aβ, the arrow shows parenchymal plaques.

Figure 9. MicroPET/CT Imaging. APP/PS1 and WT mice (15 months old; n = 3; closely age-matched) were
injected intravenously with HPLC-purified [18F]-9 (5.032 MBq). Representative PET static images of brain
(Coronal, Axial, and Sagittal View) were obtained from 15–30 min post intravenous injection, and co-registered
with CT for an anatomical reference. The scale shows a range (Min-Max) of 0–2.046 ×  105 Bq/mL. Bottom:
APP/PS1 mouse, Top. WT mouse. While arrow indicates cortex, the arrowhead depicts cerebellum; Note higher
retention of [18F]-9 in the brains of APP/PS1 (bottom) compared with WT counterpart (top).
did not show differences consistent with spatial localization of Aβin brains of PS1/APP mice models compared
with controls, [18F]-9 shows statistically significant differences between PS1/APP transgenic mice and age-matched
WT brains. The differences between these tracers in this rodent model could be attributed to ability of [18F]-9 for
targeting both diffuse and fibrillary plaques. To further evaluate, whether or not [18F]-9 offers significant advantage over other approved tracers, the agent would need to be further investigated for its performance in other AD
rodent models (APP23 and Tg2576). Nevertheless, the preclinical data indicate that [18F]-9 could provide a novel
benzoselenazole based PET tracer, worthy of further evaluation to enable interrogation of Aβload within the brain.
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Figure 10. Dynamic PET scans were performed for 60 min following injection of [18F]-9 (5.032 MBq), and
TAC (time activity curve) represent whole brain radioactivity post-intravenous injection of [18F]-9 in agematched APP/PS1 and BL6 mice. The data were normalized to average count between 30 sec and 3 min time
points.

Conclusions

A novel heterocyclic benzoselenazole derivative 5 was synthesized and structurally characterized. Crystal structure revealed a planar geometry25 with fluorine atoms deviating out of the plane, and the presence of intermolecular and intramolecular hydrogen bonding. The agent demonstrates potent binding affinity to autopsy confirmed
AD homogenates and the binding affinity constant is superior to that of [18F]-AV-4541, [18F]-Florbetaben40, and
[18F]-Flutemetamol42. Competitive binding displacement experiments indicate that [18F]-9 tracer targets the high
affinity binding site on AD homogenates, visualized by [11C]-PiB via PET imaging (data not shown). Importantly,
[18F]-9 labels Aβplaques in cortex of autopsy confirmed AD brain sections, while also demonstrating a close
immunohistochemical correlation with anti Aβantibody-conjugate thereby indicating specificity for mapping
the biomarker protein. The fluorescent molecule 5 detects Aβplaques in brain hippocampus sections of transgenic mice, while also visualizing CAA. Noticeably, 5 labels both diffuse and fibrillar plaques in brain sections
of AD patients, while lacking interaction with biomarker proteins of other neurodegenerative diseases thereby
indicating specificity for detecting Aβin AD. The ability of 5 to detect diffuse plaques (the precursor to fibrillar
neuritic plaques) in AD brain tissue sections could be beneficial in stratification of subjects with a risk factor for
development of AD, while also enabling quantitative assessment of overall efficacy of anti-amyloid therapeutics.
Finally, Fluselenamyl demonstrates favorable biological half-life in human serum, facile brain penetration, and
ability to detect parenchymal plaques in transgenic mice, minutes post-intravenous injection. Overall, these data
provide a provocative platform for further development of PET tracers comprising benzoselenazoles moiety in
their organic scaffold to enable noninvasive assessment of Aβ plaques in vivo. Further investigations evaluating
ability of 5 to map Aβburden in various AD rodent models as a function of aging are under progress.
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